Introduction

Congenital peribronchial myofibroblastic tumor (CPMT) is a rare tumor of childhood that is thought to develop during the early weeks of intrauterine life. It is usually associated with hydrops fetalis and polyhydramnios, and can be detected during prenatal evaluation by ultrasonography. We have found 15 cases in the English-language clinical literature; six of these cases were reported as doing well at 3 months to 6.5 years after resection. In this report, we present the seventh surviving patient, with radiographic, gross, and microscopic features of the tumor, together with a review of the literature.

Case Report

A 38 year-old female patient, gravida five, para two, abortus one (G5P2A1), at 35 weeks of gestation, was referred to the obstetrics department of our institute with polyhydramnios. She was married to a relative, a maternal cousin. Her first child had died 3 days after birth of unknown causes. Her second and third children are 17 and 15 years old, with no health problems. Her fourth pregnancy was a miscarriage at 21 weeks of gestation. An autopsy performed on this foetus had revealed omphalocele, olygodactyly of the left foot, and flexion deformity of the left hand.

Our case was her fifth pregnancy. Prenatal ultrasonography at 35 weeks revealed polyhydramnios, hydrothorax, and a mass in the right lung. The male neonate was delivered by caesarean section, right lobectomy was performed. The tumor was limited to the lung, and was composed of spindle cells, proliferating around a bronchial unit. Central necrosis and 4-5 mitoses per 10 high power fields were present. The patient is well 26 months after surgery.

Pathological Findings

The mass removed at lobectomy was well circumscribed, with no true capsule, and was 6.5x5.5 cm in size (Figure 2). There was a small area of compressed lung tissue surrounding the mass. Its cut surface was solid and grey-tan, with necrotic areas at the centre.

Microscopically, lung parenchyma was replaced by well-circumscribed, non-encapsulated mesenchymal tumor (Figure 3). Tumor cells were uniformly spindle-shaped, with finely granular chromat (Figure 4). There was no anaplasia or pleomorphism. Tumor cells were surrounding the bronchial walls, but not compressing them. Central necrosis was pres-
There were four to five mitoses per ten high power fields (HPF), but no atypical mitoses. There was another small focus of spindle cell proliferation around a bronchioalveolar unit near the tumor, which indicated multifocality (Figure 3).

Immunohistochemically, tumor cells were strongly positive for vimentin. Staining for smooth muscle actin (SMA), desmin, S-100, CD34, human herpesvirus-8 (HHV-8), activin receptor-like kinase-1 (ALK-1), AFP, and NSE were negative.

Discussion

Congenital peribronchial myofibroblastic tumor is a rare neoplasm of childhood, first described by Jones in 1949 as an unusual hamartoma (1). Morphologically similar tumors were identified as congenital fibrosarcoma, congenital leiomyosarcoma, or congenital mesenchymal malformation until 1993, when McGinnis first used the term CPMT (2). This term was more useful, because of the tumor’s favourable outcome, in spite of its morphology. A summary of the English-language reported cases is given in Table 1 (3-14).

Congenital peribronchial myofibroblastic tumor is thought to develop from pluripotent mesenchymal cells, which are destined to differentiate into cartilage or myofibroblasts. Immunohistochemistry and electron microscopy findings support this theory. Immunohistochemically, tumor cells were positive for vimentin in all of the studied cases. Focally, SMA positivity was also reported in three cases (10, 13, 14), but was negative in others, as in our case. Electron microscopic evaluation suggested a myofibroblastic differentiation. Ultrastructurally, spindle-shaped cells’ cytoplasm contained rough endoplasmic reticulum, mitochondria, ribosomes, lysosomes, and a few lipid droplets; some showed bundles of actin filaments (10).

Huppman et al. (13) drew attention to the abundance of mature cartilage in postnatal resection specimens, as compared to a prenatal resection specimen from the same patient in their study. This observation was consistent with their theory that cartilaginous differentiation of the tumor cells was occurring. This was not similar to our case, as we did not see a cartilage component to the tumor.
Histopathological findings are similar in the literature; i.e., cellular spindled myofibroblastic cells proliferating around the bronchial cartilage. Central necrosis was reported in three cases, all at the centre of the tumors (10, 11, 12). Thus, this is a coagulation necrosis, rather than a tumor necrosis. Mitotic activity ranged from zero to five mitoses per high power field in the literature (Table 1).

Our case presents an additional finding to those of the previously reported 15 cases. There was an abortus history of a malformed foetus of this mother, 1 year before this birth. Consanguineous marriage of the parents seems to be the most likely reason for the malformations of that foetus, supporting a genetic defect theory in the pathogenesis of CPMT. Only one report with cytogenetic analysis has been published, which noted a complex rearrangement involving chromosomes 4, 8 and 10, (10) which differed from observations of leiomyosarcoma and fibrosarcoma. Unfortunately, we could not perform chromosomal analyses on any siblings in the present case.

When histopathological and clinical features are considered together, differential diagnosis of a lung mass in children mainly includes hamartoma, inflammatory myofibroblastic tumor, pleuropulmonary blastoma, and congenital fibrosarcoma.

Histologically, hamartomas are usually easy to recognize because of their cartilage, fat, fibrous tissue, bone, and smooth muscle components.

Table 1. The summary of the cases reported in the literature

<table>
<thead>
<tr>
<th>Author</th>
<th>Diagnosis</th>
<th>Gestational Age</th>
<th>Sex</th>
<th>Outcome</th>
<th>Site</th>
<th>Cartilaginous Component</th>
<th>Mitosis</th>
<th>Necrosis</th>
<th>Hydrops</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones (1)</td>
<td>Hamartoma</td>
<td>28 weeks</td>
<td>F</td>
<td>Died 1 hour after birth</td>
<td>RUL</td>
<td>+</td>
<td>N/A</td>
<td>N/A</td>
<td>-</td>
</tr>
<tr>
<td>McGinnis (2)</td>
<td>CPMT</td>
<td>33 weeks</td>
<td>M</td>
<td>3 days (intraoperative death)</td>
<td>RUL</td>
<td>+</td>
<td>Average 1/10 HPF</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Robb (3)</td>
<td>Neonatal Fibrosarcoma</td>
<td>N/A</td>
<td>M</td>
<td>Well at 10 months</td>
<td>LLL</td>
<td>-</td>
<td>Present but not numerous</td>
<td>N/A</td>
<td>-</td>
</tr>
<tr>
<td>Guccion (4)</td>
<td>Leiomyosarcoma</td>
<td>N/A</td>
<td>M</td>
<td>Died shortly after birth</td>
<td>LUL</td>
<td>-</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Jimenez (5)</td>
<td>Leiomyosarcoma</td>
<td>36 weeks</td>
<td>M</td>
<td>Well at 34 months</td>
<td>RLL</td>
<td>-</td>
<td>Occasional</td>
<td>N/A</td>
<td>+</td>
</tr>
<tr>
<td>Pettinato (6)</td>
<td>Fibrosarcoma</td>
<td>N/A</td>
<td>M</td>
<td>Well at 6 years</td>
<td>RLL</td>
<td>-</td>
<td>Variable</td>
<td>N/A</td>
<td>Pleural effusion</td>
</tr>
<tr>
<td>N/A</td>
<td>M</td>
<td>Well at 3 months</td>
<td>LUL</td>
<td>-</td>
<td>-</td>
<td>None</td>
<td>N/A</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Haller (7)</td>
<td>Mesenchymal tumor</td>
<td>40 weeks</td>
<td>F</td>
<td>Died at 8 hours</td>
<td>LLL</td>
<td>-</td>
<td>None</td>
<td>N/A</td>
<td>+</td>
</tr>
<tr>
<td>Warren (8)</td>
<td>Mesenchymal malformation</td>
<td>30-33 weeks</td>
<td>F</td>
<td>24 hours (surgery complication)</td>
<td>LUL/LLL</td>
<td>N/A</td>
<td>1-5/HPF</td>
<td>N/A</td>
<td>-</td>
</tr>
<tr>
<td>Khong (9)</td>
<td>Mesenchymal malformation</td>
<td>27 weeks</td>
<td>M</td>
<td>At birth</td>
<td>RUL</td>
<td>+</td>
<td>Frequent</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Alobeid (10)</td>
<td>CPMT</td>
<td>35 weeks</td>
<td>F</td>
<td>Well at 1 2 months</td>
<td>RML/RLL</td>
<td>Not neoplastic</td>
<td>0-3/10 HPF</td>
<td>+</td>
<td>N/A</td>
</tr>
<tr>
<td>Reiss (11)</td>
<td>CPMT</td>
<td>25 weeks</td>
<td>M</td>
<td>Termination</td>
<td>L</td>
<td>-</td>
<td>0-4/10 HPF</td>
<td>+</td>
<td>Small pleural effusion</td>
</tr>
<tr>
<td>Horikoshi (12)</td>
<td>CPMT</td>
<td>30 weeks</td>
<td>M</td>
<td>IUFD</td>
<td>LLL</td>
<td>-</td>
<td>N/A</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Huppmann (13)</td>
<td>CPMT</td>
<td>23 weeks/ 6 weeks</td>
<td>M</td>
<td>Well at 6.5 years</td>
<td>LUL/LLL</td>
<td>+</td>
<td>Brisk in prenatal resection</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>de Noronha (14)</td>
<td>CPMT</td>
<td>24 weeks</td>
<td>M</td>
<td>IUFD</td>
<td>LLL</td>
<td>Immature cartilage</td>
<td>Frequent</td>
<td>N/A</td>
<td>+</td>
</tr>
<tr>
<td>Present case</td>
<td>CPMT</td>
<td>12 days</td>
<td>M</td>
<td>Well at 26 months</td>
<td>LML</td>
<td>-</td>
<td>4-5/10 HPF</td>
<td>+</td>
<td>Hydrothorax</td>
</tr>
</tbody>
</table>
Inflammatory myofibroblastic tumors consist of bland spindled and stellate cells with abundant eosinophilic cytoplasm, admixed with scattered inflammatory cells. Immunohistochemically, these myofibroblastic cells are positive for SMA and ALK.

Pleuropulmonary blastoma is a rare malignant embryonic mesenchymal neoplasm, with solid and cystic patterns. The solid pattern may cause difficulty in diagnosis, when it contains fibrosarcoma-like areas. These areas are usually focal, and the rhabdoid appearance of the cells in other tumor areas is a helpful diagnostic finding.

Another quite rare malignant tumor, congenital fibrosarcoma, should also be kept in mind, due to its histological resemblance to CPMT. In fact, some past CPMT cases were identified as congenital fibrosarcoma. Fortunately, this tumor is principally located in the extremities. Histologically, nearly uniform spindle cells are arranged in bundles and fascicles, and mitotic activity varies among different areas of the same tumor. Immunohistochemically, SMA is variably positive.

Fifteen cases may not be enough to reach general conclusions about the features of this tumor, because nine of the patients died either during the intrauterine period or within a short time after surgery, as a result of probable surgical complications (Table 1).

The common findings of the reported cases are that CPMT is a highly cellular mesenchymal tumor, which may appear threatening to the pathologist with its possible necrosis and variable levels of mitosis. The consensus is that all seven surviving patients, including our case, had an excellent outcome after successful surgery. Therefore, it is important to keep this microscopically concerning, but otherwise indolent, lung mass in mind during the evaluation of pregnant women presenting with polyhydramnios due to an intrathoracic mass.

**Ethics Committee Approval:** This case report was not directly realized on human subject but on human tissue samples archived in the collection of the Department of Pathology of Medical Faculty in Çukurova University so Ethics Committee Approval was not indicated.

**Informed Consent:** Written informed consent was obtained from the patient’s father.

**Peer-review:** Externally peer-reviewed.


**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors don’t have any financial disclosure relevant to this study.

**References**